More tools:Markets·Screener·Research·Chat

Innate Pharma S.A. ADS (IPHA) Financial Statements

Innate Pharma S.A. ADS
SIC 8731 · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
FIGI BBG009ZCBWH4
XNAS · usd
2.05▼ 0.03 (-1.44%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close2.08
Day's Range2.00 – 2.06
52-Week Range1.18 – 2.71
Volume27.5K
Avg Volume284.0K
Share Statistics
Shares Outstanding
Employees163
ExchangeXNAS
Listed2015-09-09
Share count as of December 31, 2025
Loading Income Statement…
Key questions about Innate Pharma S.A. ADS (IPHA)
What is Innate Pharma S.A. ADS's Market Cap?
Innate Pharma S.A. ADS's Market Cap is $192.1M, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's Enterprise Value?
Innate Pharma S.A. ADS's Enterprise Value is $159.2M, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's Price / Sales?
Innate Pharma S.A. ADS's Price / Sales is 18.2×, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's EV / Revenue?
Innate Pharma S.A. ADS's EV / Revenue is 15.1×, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's EV / EBITDA?
Innate Pharma S.A. ADS's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's Revenue (TTM)?
Innate Pharma S.A. ADS's Revenue (TTM) is $10.6M, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's Net Income (TTM)?
Innate Pharma S.A. ADS's Net Income (TTM) is -$57.7M, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's EBITDA?
Innate Pharma S.A. ADS's EBITDA is -$61.8M, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's Diluted EPS (TTM)?
Innate Pharma S.A. ADS's Diluted EPS (TTM) is -0.62, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's EBITDA Margin?
Innate Pharma S.A. ADS's EBITDA Margin is -584.4%, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Revenue and other income
Revenue from collaboration and licensing agreements
Government financing for research expenditures
Other income
Total revenue and other income
Operating expenses
Research and development expenses
General and administrative expenses
Impairment of intangible assets
Total operating expenses
Operating income (loss)
Financial income
Financial expenses
Net financial income (loss)
Net income (loss) before tax
Net income (loss) from continuing operations
Net income (loss)